This session will provide an in-depth exploration of the role the microbiome plays in overall health and its impact on the pathogenesis and recurrence of Clostridioides difficile infection (rCDI). Attendees will gain a comprehensive understanding of the mechanisms behind rCDI, including the significant burden it places on patients both during and after acute infection.

We will delve into the microbial composition, potency, and standardized manufacturing process of REBYOTA® (fecal microbiota, live-jslm), an FDA-approved therapeutic option for rCDI. Participants will have the opportunity to review key efficacy and safety data from clinical trials, providing evidence of REBYOTA® in clinical settings.
Through patient case studies, we will also discuss the practical application of REBYOTA® in real-world clinical practice, offering valuable insights into its role in managing and preventing rCDI recurrence. This session is ideal for health care professionals looking to deepen their knowledge of microbiome-related diseases and explore innovative treatments for recurrent CDI.

Learning Objectives: At the conclusion of this session, learners will be able to: 

• Understand the role of the microbiome in overall health, pathogenesis of Clostridioides difficile infection (CDI), and the burden of rCDI
• Learn about REBYOTA®, review efficacy and safety data, and discuss patient case studies
• Review step-by-step how to administer REBYOTA® 

This webinar does not offer any continuing education credits or recertification units.